Articles By Jack Cush, MD
FDA Approves Tildrakizumab for Psoriatic Arthritis
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
Read Article
Mixed Drinks, Mixed Results (10.30.2026)
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Read Article
Beyond Chondrocalcinosis - What’s New in CPPD Disease
An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and potential future targeted therapies. This review builds on other important reports on CPPD.
Read Article
The Efficacy of Ianalumab in Sjögren’s Disease
The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.
Read Article
2026 BSR Guideline for the Treatment of Polymyalgia Rheumatica
Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients who will require chronic glucocorticoids.
Read Article
Rituximab or Azathioprine for EGPA Maintenance?
A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone.
Read Article
Double Trouble (10.23.2026)
Dr. Jack Cush reviews the journal articles and regulatory announcements from this past week on RheumNow, including: two crystals in one joint, twice the cryptococcus risk in JAKs; Myositis and Scleroderma; and Sjögren’s plus early damage = >> 2 fold risk lymphoma. Double trouble week on the RheumNow podcast.
Read Article
van Vollenhoven’s Treatment Advances in Lupus
Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.
Read Article
Monogenic Inflammatory Disorders Go Unrecognized
Lancet Rheumatology has published a large cohort analysis with a genome-first approach using whole exome sequencing to find 1 in 4026 prevalence (159/640092) of monogenic disorders, half with inflammatory features.
Read Article
Impact of Myositis in Scleroderma Patients
Systemic sclerosis (SSc) may have overlap features such as myositis. When present, myositis in SSc is associated with an increased risk of cardiac involvement and a shift in mortality away from ILD towards a greater cardiac risk.
Read Article